1. Home
  2. CBLL vs PHAT Comparison

CBLL vs PHAT Comparison

Compare CBLL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CeriBell Inc.

CBLL

CeriBell Inc.

HOLD

Current Price

$16.45

Market Cap

750.1M

Sector

N/A

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$12.04

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBLL
PHAT
Founded
2014
2018
Country
United States
United States
Employees
280
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
750.1M
894.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CBLL
PHAT
Price
$16.45
$12.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$23.20
$19.83
AVG Volume (30 Days)
285.3K
1.4M
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$29.57
$93.04
Revenue Next Year
$28.44
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$10.85
$3.69
52 Week High
$24.33
$18.31

Technical Indicators

Market Signals
Indicator
CBLL
PHAT
Relative Strength Index (RSI) 31.17 48.15
Support Level $11.17 $10.38
Resistance Level $20.25 $12.52
Average True Range (ATR) 1.10 0.98
MACD -0.52 -0.01
Stochastic Oscillator 9.80 61.97

Price Performance

Historical Comparison
CBLL
PHAT

About CBLL CeriBell Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: